Meeting
2018 ASCO Annual Meeting
Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).
Authors
Anna F. Farago
Massachusetts General Hospital, Boston, MA
Anna F. Farago , Benjamin Jacob Drapkin , Allison Charles , Beow Y Yeap , Rebecca Suk Heist , Christopher G. Azzoli , David Michael Jackman , J Paul Marcoux II, David Allen Barbie , David T. Myers , Sarah Phat , Jun Zhong , Jane Bailey Grinnell , Lecia V. Sequist , Mari Mino-Kenudson , Shyamala Maheswaran , Daniel A. Haber , Aaron N. Hata , Nicholas John Dyson , Alice Tsang Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02446704
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8571)
DOI
10.1200/JCO.2018.36.15_suppl.8571
Abstract #
8571
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
First Author: Joseph W. Kim
Poster
2023 ASCO Annual Meeting
Phase II study of durvalumab plus olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): Preliminary efficacy and safety results.
First Author: Yan Huang
Poster
2020 ASCO Virtual Scientific Program
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
First Author: Navid Hafez
Poster
2012 ASCO Annual Meeting
Safety and efficacy results from two randomized expansions of a phase I study of a tablet formulation of the PARP inhibitor, olaparib, in ovarian and breast cancer patients with BRCA1/2 mutations.
First Author: L Rhoda Molife